Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelizumab with extracranial radiotherapy after first-line treatment for extensive-stage small cell lung cancer
ChiCTR2400089941Phase 4Not yet recruiting
- Sponsor
- Nanjing Tianyinshan Hospital
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adebelizumab in small cell lung cancer (SCLC) (2 arms), sponsored by Nanjing Tianyinshan Hospital. Primary endpoints: Progression-free survival, Overall survival and 2 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
adebelizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400089941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089941.